Goldman Sachs maintains its Neutral rating on Clorox Co (NYSE: CLX, despite its fourth-quarter results missing estimates as higher costs offset
volume gains.
The results showed that the company's positive gross margin streak came to an end amid fading input costs benefit and increasing
price investments due to stiff competition. But, volume gains displayed "surprising" resiliency.
"While the optics of the strong 4Q volume growth (nearly +6 percent) raises questions of sustainability, we believe the growth
is in part sustainable and view the low end of its 2–4 percent organic sales target next year as achievable on volume gains alone,"
analyst Jason English wrote in a note.
"The high-end, however, strikes us as likely out of reach, especially given onerous comparisons this year," English
continued.
Related Link: Clorox Sees
FY 2017 EPS $5.13 to $5.28 vs $4.95 est
In addition, the analyst raised his FY17 estimates to reflect the new accounting changes. English now expects FY17 EPS of $5.45 (up from $5.21) on
revenue of $5.96 billion (up from $5.97 billion).
Further, English cut the price target on the stock by $1 to $130 to reflect slowing fundamentals and accounting-adjustment
inflation of EPS.
Shares of Clorox closed Wednesday's regular trading session at $131.59, and were up 1.21 percent to $133.18 at time of writing
Thursday.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
Latest Ratings for CLX
Date |
Firm |
Action |
From |
To |
Jul 2016 |
Deutsche Bank |
Maintains |
|
Hold |
Jun 2016 |
Atlantic Equities |
Initiates Coverage on |
|
Neutral |
May 2016 |
JP Morgan |
Maintains |
|
Underweight |
View More Analyst Ratings for
CLX
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.